Health Equity

hero image for desktop

Health Equity in Prostate Cancer Care

Black men are disproportionately affected by prostate cancer, including higher rates of diagnosis and mortality. Health equity focuses on removing barriers to screening, diagnosis, treatment, and support so every patient has the opportunity to achieve the best possible outcome.

1 in 6 Black men will develop prostate cancer in their lifetime, compared with about 1 in 8 men overall.1,2

Black men are twice as likely to die from prostate cancer compared with White men.3

Black men are often diagnosed at a younger age and more likely diagnosed with advanced-stage disease.4

Patient Videos

Voices of Black Men with Prostate Cancer

Patient Perspective

Prostate Cancer Awareness for Black Men

ABC News correspondent and prostate cancer survivor Steve Osunsami shares his experience and discusses breaking the stigma surrounding prostate cancer in the Black community. He emphasizes the importance of understanding family history, discussing earlier PSA screening, and encouraging open conversations about prostate cancer and men's health.

Clinician Insights and Resources

Addressing Health Equity in Prostate Cancer Care

Expert Perspective

Black Men and Prostate Cancer Screening

Learn why earlier PSA screening may be recommended for Black men and how individual risk factors, family history, and health equity can influence prostate cancer detection and outcomes.

Health Equity

Prostate Cancer Risk Factors in Black Men

Black men face a higher risk of prostate cancer and are more likely to be diagnosed at a younger age. Guidelines recommend considering earlier PSA screening, often between ages 40 and 45. Patients should discuss when to begin screening with their healthcare provider based on individual risk factors and preferences.

Learn More

Expert Perspective

Somatic and Germline Testing for Prostate Cancer

Learn how inherited and tumor-based genetic testing can help inform prostate cancer risk, treatment decisions, and family counseling.

Expert Perspective

The Importance of Equity in Prostate Cancer Clinical Trials

Learn why diversity and representation in prostate cancer clinical trials matter and how addressing barriers to participation can improve access to care and treatment outcomes for all patients.

 

References

1. Saka AH, Giaquinto AN, McCullough LE, Tossas KY, Star J, Jemal A, Siegel RL. Cancer statistics for African American and Black people, 2025. CA: A Cancer Journal for Clinicians. 2025;75(2):106-132. doi:10.3322/caac.21874.

2. American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. Available online. Accessed August 12, 2026.

3. Centers for Disease Control and Prevention. Cancer and African American People. CDC Cancer and Health Equity. U.S. Department of Health and Human Services. Accessed June 23, 2026. Veterans Health Library. Last annual review date: February 1, 2026. Accessed June 16, 2026.

4. Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: A literature review. Cancer. 2023;129(1):16-28. doi:10.1002/cncr.34433. PMID: 36066378. PMCID: PMC9826514.

This page was produced with the generous support of AstraZeneca Pharmaceuticals